Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Submit your abstract for ESMO Asia 2024, 6-8 December, Singapore! Don't miss the chance to present your research and join us in advancing oncology. Merit Travel Grants available
Gain deeper understanding and register for the ESMO Deep Dive: Breast Cancer webinar, available to all ESMO members
Keep up to date with practice-changing publications in ovarian cancer, HCC, advanced breast cancer, and join the discussion with key opinion leaders
Amplify the impact of your work and contribute to the global fight against cancer
Explore the leading-edge scientific and educational materials
Browse the high quality scientific and educational content from the ESMO Gynaecological Cancers Congress 2024
Online application is open until 10 July 2024
Online application is now open until 16 Jul 2024
Online application is now open until 16 Jul 2024
Online application is now open until 23 Jul 2024
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
A new version prepared by F. Lordick and E. Smyth
The resources for this webinar include expert insights from the latest ESMO Living Guidelines applied to real clinical scenarios
Edited by Christina Fotopoulou, Antonio González-Martín, Marcia Hall
Benefits reported for the combination of ipilimumab and nivolumab further expand alternative therapeutic options for patients with unresected advanced disease
Novel agents, a rethinking of accepted treatment concepts and new roles for older treatment modalities are now driving liver cancer management
Data from clinical trials show the value of liquid biopsy in treatment decision-making and prognostication
Lessons learned about the importance of the gut microbiome composition in immune checkpoint inhibitor therapy response could be crucial in tailoring cancer care
In the TRANSMET trial, a 5-year overall survival benefit was observed in a highly selected patient population
Final results of the KEYNOTE-585 study indicate that the current treatment standard for resectable G/GEJ should remain unchanged
Promising data from a subgroup analysis of the phase III NETTER-2 study support the use of peptide receptor radionuclide therapy in treatment-naïve patients
Innovative approaches are investigated to predict cancer development in patients with cirrhosis and detect early recurrence after resection
The development of KRAS selective inhibitors promises to expand treatment to a broader population of patients with KRAS-mutated tumours
Benefits reported for the combination of ipilimumab and nivolumab further expand alternative therapeutic options for patients with unresected advanced disease
Evidence for efficacy is based on the results from the LIBRETTO-001 study
Hundreds of trials are being delayed in Europe due to unintended consequences of the IVDR posing an existential threat to Europe’s role as a leader in global oncological research
Findings from a real-life cohort of women aged at least 30 years who attended cervical cancer screening in Stockholm
Novel agents, a rethinking of accepted treatment concepts and new roles for older treatment modalities are now driving liver cancer management
Data from clinical trials show the value of liquid biopsy in treatment decision-making and prognostication
Lessons learned about the importance of the gut microbiome composition in immune checkpoint inhibitor therapy response could be crucial in tailoring cancer care
It is indicated for in vitro radiolabelling of various kits for radiopharmaceutical preparation developed and approved for radiolabelling used for PET imaging
ESMO would like to thank the Hellenic Society of Medical Oncology (HeSMO) for providing translation in the Greek language
Evidence for efficacy is based on the results from the LIBRETTO-001 study
Findings from a real-life cohort of women aged at least 30 years who attended cervical cancer screening in Stockholm
It is indicated for in vitro radiolabelling of various kits for radiopharmaceutical preparation developed and approved for radiolabelling used for PET imaging
Findings from a long-term survival analysis of the DESTINY-Breast03 study
In POSITIVE study, menstruation resumptions occurred mostly during the first 6 months, with young age being the most determinant factor
Evidence for efficacy is based on the results from the IMerge study
Findings from the CONTINUUM study
It is intended for the first-line treatment of patients with metastatic non-oncogene addicted NSCLC in combination with platinum-based chemotherapy
Findings from the MOTION study
Treatment of gastrointestinal (GI) cancers is catching up with other areas of oncology and offering patients better prospects for survival and quality of life, but a significant uptick in early-onset cases is raising new questions about effective prevention, diagnosis and treatment
Cross-border tumour boards of cancer specialists from different European countries meeting virtually to review the management of individual patients with complex rare gynaecological cancers from across Europe resulted in new treatment recommendations and increased access to clinical trials, according to results from a six-year study that will be presented at the ESMO Gynaecological Cancers Congress 2024
The European Society for Medical Oncology is pleased to announce the ESMO Gastrointestinal Cancers Congress 2024, the scientific congress entirely dedicated to the presentation of advances and discussions around the prevention, diagnosis and management of malignancies of the gastrointestinal tract
The ESMO Gynaecological Cancers Congress 2024 will be held in Florence, Italy, between 20-22 June, hosting international experts who will present and discuss the latest developments in the biology, diagnosis and therapy of gynaecological tumours
Ahead of World No Tobacco Day 2024, European scientific, healthcare professional and other civil society organisations call for an EU Endgame on Tobacco
First global study in young women with high-risk genes and a pregnancy after breast cancer shows Assisted Reproductive Techniques (ART) are safe, with no increase in breast cancer recurrence
ESMO Breast Cancer 2024 will be held in Berlin, Germany, between 15-17 May where the latest research in breast cancer will be presented
The European Lung Cancer Congress 2024 is the annual appointment that brings together various experts in the field of thoracic oncology
The ESMO Sarcoma and Rare Cancers Congress 2024 will be held in Lugano from 14 to 16 March and will bring together world-renowned experts among researchers and practitioners, to present and discuss the latest advances in the treatment and care of sarcoma and rare cancers in general
Hundreds of trials are being delayed in Europe due to unintended consequences of the IVDR posing an existential threat to Europe’s role as a leader in global oncological research
The Impact Factor (IF) of ESMO journals has remained strong this year, according to the 2024 Journal Citation Reports published by Clarivate Analytics
ESMO has announced today the results of its Presidential elections following the closure of the voting system on Monday, 10 June 2024.
Tom Powles, Editor in Chief of ESMO’s flagship journal Annals of Oncology; Solange Peters, ESMO Past President; and Fabrice André, President Elect of the Society have been recognised as leading and influential researchers for their remarkable achievements in cancer care
Following the Ombudsman’s recent findings of maladministration regarding the Commission’s interactions with tobacco lobbyists and its subsequent decision not to bring forward the proposed Council recommendation on smoke-free environments, it is beyond belief that the Commission now appears to have removed plans to publish an evaluation – originally meant to come in 2022 - of the Tobacco Products Directive from its implementation
The European Society for Medical Oncology (ESMO) announced today that the 2024 ESMO Breast Cancer Award is conferred to Hope S. Rugo, Professor of Medicine and Winterhof Family Professor of Breast Cancer at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
The European Society for Medical Oncology (ESMO) announced today that the 2024 Heine H. Hansen Award is bestowed to Enriqueta Felip
The nomination process for the 2024 ESMO Society Awards is now open
ESMO is pleased to announce the newly appointed Committee and Working Group Chairs who started their mandates in January 2024
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Switzerland
Germany
Switzerland
Spain
Portugal
Portugal
Republic of Singapore
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Members: the main session of the ESMO Examination 2023 will be held on Saturday 21 October during the ESMO Congress 2023.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
